Key Updates
Moderna shares advanced 2.29% to $43.93 since the last report, extending the recovery rally to 48.97% YTD as the company delivered Q4 earnings that exceeded expectations and articulated a credible international expansion strategy. The stock continues its rebound from the FDA flu vaccine rejection, gaining 56.78% over six months as management demonstrated resilience by pivoting away from U.S. regulatory uncertainty toward international markets while maintaining its 10% revenue growth target for 2026. The earnings beat, combined with strategic partnerships in Europe, Latin America, and Asia Pacific, has reinforced investor confidence in the post-COVID business model despite ongoing regulatory headwinds.
Current Trend
Moderna maintains a robust uptrend with 48.97% YTD gains, building on the 45.63% YTD performance from the previous report. The stock has established a clear recovery pattern from the FDA-induced selloff, with the $39-40 level serving as strong support during the February 10-12 decline. Current price action at $43.93 represents a 12.7% recovery from the post-FDA rejection lows, with the stock consolidating recent gains. The 56.78% six-month rally indicates sustained institutional accumulation, while short-term momentum remains positive across all timeframes (1d: +4.03%, 5d: +4.72%, 1m: +5.02%). The stock has broken above the $43 resistance level, suggesting potential for further upside toward pre-rejection levels near $45-46.
Investment Thesis
The investment thesis centers on Moderna's successful transition from COVID-19 dependency to a diversified mRNA platform company with three approved products and multiple late-stage pipeline assets. The company's strategic pivot to international markets addresses U.S. regulatory uncertainty while targeting the $1.8 billion European respiratory vaccines market and expanding through government partnerships in the U.K., Canada, and Australia. Revenue visibility is improving with 85% of 2026 revenue expected in the second half and international sales projected to reach 50% of total revenue versus 62% U.S. exposure in 2025. The cancer vaccine collaboration with Merck, showing 49% reduction in melanoma recurrence risk after three years, represents a potentially transformative opportunity beyond seasonal vaccines. However, the thesis faces execution risk from the $3 billion annual R&D spend, negative operating margins of -157.3%, and $2 billion annual cash burn against $5.5-6 billion projected year-end cash reserves.
Thesis Status
The thesis has strengthened materially since the last report. Q4 revenue of $678 million exceeded Wall Street estimates of $626 million, demonstrating that U.S. COVID vaccine demand declined only 26% in 2025 versus anticipated 40%, providing better-than-expected baseline revenue. Management's decision to abandon new U.S. late-stage vaccine trials and focus on international markets directly addresses the regulatory uncertainty that triggered the recent selloff. The 24% U.S. retail market share for the next-generation mNexspike COVID vaccine validates product competitiveness despite reduced overall market size. Cost discipline is evident with 31% R&D expense reduction, though the path to 2028 breakeven now depends more heavily on international expansion and the cancer vaccine franchise. The FDA flu vaccine rejection remains a setback, but the application's active review in the EU, Australia, and Canada preserves significant revenue potential outside the U.S. market.
Key Drivers
Q4 earnings beat represents the primary catalyst, with revenue of $678 million exceeding estimates while narrowing the quarterly loss to $2.11 per share from $2.91 per share year-over-year. The international expansion strategy drove shares up more than 7% on February 13, with management confirming partnerships in multiple geographies and projecting international sales to reach 50% of revenue in 2026. The FDA flu vaccine rejection continues to create uncertainty, with the decision attributed to new vaccine division head Vinay Prasad's reversal of previously approved trial protocols. Regulatory environment deterioration is evidenced by management's decision to halt new U.S. late-stage vaccine investments and the cancellation of a $600 million government mRNA vaccine contract. The melanoma vaccine Phase 2b results showing 49% reduction in recurrence risk after three years provides pipeline validation beyond seasonal vaccines.
Technical Analysis
Moderna exhibits strong bullish momentum with the stock trading at $43.93, up 2.29% from the previous report and establishing a higher low pattern above the $40 support level. The 48.97% YTD gain places the stock well above its 200-day moving average, while the 56.78% six-month rally indicates a sustained uptrend. Price action has formed a V-shaped recovery from the February 10 FDA rejection selloff, with the stock reclaiming the $43 level and consolidating gains. Near-term resistance sits at $45-46, representing pre-rejection levels, while support has solidified at $40-41 based on the recent earnings-driven bounce. Volume patterns suggest institutional accumulation, with the 7% single-day gain on February 13 occurring on elevated volume. The RSI likely remains in bullish territory without being overbought, supporting continuation of the uptrend. A breakout above $46 would target the $50 psychological level, while failure to hold $40 would signal renewed selling pressure.
Bull Case
- Q4 revenue beat and better-than-expected COVID demand trends: Revenue of $678 million exceeded Wall Street estimates of $626 million, while U.S. COVID vaccine demand declined only 26% in 2025 versus the anticipated 40% drop, providing a more resilient baseline business. Source: Bloomberg
- International expansion strategy with confirmed government partnerships: Management projects international sales will reach 50% of 2026 revenue versus 62% U.S. exposure in 2025, with strategic agreements in the U.K., Canada, Australia, Latin America, and Asia Pacific targeting the $1.8 billion European respiratory vaccines market. Source: Reuters
- Cancer vaccine partnership showing sustained efficacy: The melanoma vaccine collaboration with Merck demonstrated 49% reduction in recurrence or death risk after three years in Phase 2b trials, representing a potentially transformative multi-billion dollar opportunity beyond seasonal vaccines. Source: Forbes
- Market share gains in next-generation COVID vaccines: The mNexspike COVID vaccine captured 24% of the U.S. retail COVID vaccine market, validating product competitiveness and supporting the company's ability to maintain revenue despite overall market contraction. Source: WSJ
- Cost discipline and improved cash runway: Management cut R&D expenses by 31% while projecting year-end cash and investments between $5.5 billion and $6 billion, extending the runway to 2028 breakeven despite ongoing losses. Source: Bloomberg
Bear Case
- FDA regulatory uncertainty undermining U.S. market access: The FDA's refusal to review the flu vaccine application after previously approving trial protocols, combined with new vaccine division leadership reversing established guidance, creates unpredictable regulatory risk affecting the company's largest market. Source: WSJ
- Massive cash burn and path to profitability uncertainty: The company operates with negative operating margins of -157.3% and burns approximately $2 billion annually in operating cash flow while spending $3 billion on R&D in 2025, creating execution risk despite the $5.5-6 billion cash position. Source: Forbes
- Loss of $1 billion flu vaccine revenue opportunity: The FDA rejection eliminates an estimated $1 billion in potential annual revenue from the flu vaccine in the U.S. market, forcing greater reliance on international approvals and the cancer vaccine pipeline. Source: Morningstar
- Deteriorating U.S. policy environment for mRNA vaccines: The cancellation of a $600 million government mRNA vaccine contract, elimination of COVID vaccine recommendations for pregnant women and children, and management's decision to halt new U.S. late-stage vaccine trials signal structural headwinds in the domestic market. Source: Reuters
- Revenue concentration risk in second half of 2026: Management expects 85% of 2026 revenue to come in the second half of the year, creating significant execution risk and potential for earnings volatility if international expansion or seasonal vaccine uptake disappoints. Source: WSJ